|
|
Post by hellodolly on Apr 1, 2022 17:54:06 GMT -5
Not enough to buy out MNKD in my opinion, unless the orphan lung business is separated from the endocrine business. But no, still not enough.đ Or buy RLS? |
|
|
|
Post by Clement on Apr 2, 2022 7:21:27 GMT -5
I think I'm oversimplifying but I see
$1.2 billion plus
$0.8 billion plus
$0.5 billion
= $2.5 billion
|
|
|
|
Post by peppy on Apr 2, 2022 7:58:41 GMT -5
I think I'm oversimplifying but I see $1.2 billion plus $0.8 billion plus $0.5 billion = $2.5 billion I see COPD. Adding indications. Additionally UTHR is growing lung tissue.  |
|
|
|
Post by boca1girl on Apr 2, 2022 9:34:54 GMT -5
Not enough to buy out MNKD in my opinion, unless the orphan lung business is separated from the endocrine business. But no, still not enough.đ Or buy RLS? How would RLS fit into UTHRâs business? |
|
|
|
Post by hellodolly on Apr 3, 2022 16:52:34 GMT -5
How would RLS fit into UTHRâs business? I'm looking at it from the Technosphere advantage and how the technology allows deep penetration into the lungs. Anything going into the lungs, to treat a disease, I'm reaching out for. It's a stretch...but UTHR seemed to have put some of their eggs into the Technosphere basket. Who knows what else they might jump into?? |
|
|
|
Post by mymann on Apr 3, 2022 17:13:03 GMT -5
UTHR can all my shares of mnkd for $20/share. Holding since 2008. A long freaking time hoping I get my investment back.
|
|
|
|
Post by peppy on Apr 4, 2022 9:39:22 GMT -5
I think I'm oversimplifying but I see $1.2 billion plus $0.8 billion plus $0.5 billion = $2.5 billion Thank you Clement and @ sla55.  FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) FORM 8-K |
|
|
|
Post by peppy on Apr 4, 2022 11:18:14 GMT -5
I think I'm oversimplifying but I see $1.2 billion plus $0.8 billion plus $0.5 billion = $2.5 billion Thank you Clement and @ sla55 .  FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) FORM 8-K You all know the way I get. UTHR Monthly, UTHR price is heading back through its point of break out. $190.31. MNKD price head towards its point of break out which looks to be $4.90 on the wedge, wedge not shown, rats.   |
|
|
|
Post by cretin11 on Apr 4, 2022 11:33:39 GMT -5
How would RLS fit into UTHRâs business? It really doesnât at all. Nor are they going to buy MNKD, as they wouldâve done it by now if they had any desire to. They negotiated a very favorable deal with MNKD regarding TrepT, hopefully a win-win for both companies. |
|
|
|
Post by boca1girl on Apr 4, 2022 11:58:39 GMT -5
How would RLS fit into UTHRâs business? It really doesnât at all. Nor are they going to buy MNKD, as they wouldâve done it by now if they had any desire to. They negotiated a very favorable deal with MNKD regarding TrepT, hopefully a win-win for both companies. I agree with most of your points but never is a very long time. I also do not believe that UTHR will be buying MNKD but I do see more collaboration. But if we sign a deal with Roche on a COPD medicine things will get interesting since UTHR also has COPD in their pipeline. |
|
|
|
Post by cretin11 on Apr 4, 2022 15:28:07 GMT -5
Agree boca. As things stand there is no reason to believe UTHR intends to buy MNKD. But as is always the case, some âifsâ could happen to change that.
|
|
|
|
Post by hellodolly on Apr 4, 2022 16:09:54 GMT -5
It really doesnât at all. Nor are they going to buy MNKD, as they wouldâve done it by now if they had any desire to. They negotiated a very favorable deal with MNKD regarding TrepT, hopefully a win-win for both companies. I agree with most of your points but never is a very long time. I also do not believe that UTHR will be buying MNKD but I do see more collaboration. But if we sign a deal with Roche on a COPD medicine things will get interesting since UTHR also has COPD in their pipeline. I think if we see more collaboration(s), that stands alone as a multiplier and it will add tremendous value to the Technosphere platform, exponentially. The value of MNKD to other pharmaceuticals, regardless of what they treat, might lead to more deals and further MNKD pipeline development. Further down the road, much further...someone is going to buy MNKD for the platform if they have a portfolio of FDA approved drugs based on the Technosphere platform. I think it will be ripe for a M&A with a CEO that has the vision. Approval in May would mean two drugs....why not three, four, five? |
|
|
|
Post by cretin11 on Apr 4, 2022 18:42:49 GMT -5
Yes thatâs been the idea going back to the days of veins of gold and embarrassment of riches. We havenât given up yet.
|
|
|
|
Post by sr71 on Apr 17, 2022 10:55:58 GMT -5
|
|
|
|
Post by peppy on Apr 17, 2022 17:52:22 GMT -5
Mango tells stories of Al Mann being involved with mechanical items. mango mnkd.proboards.com/thread/12937/memorial-tributes-national-academy-engineeringHis entrepreneurial career began in 1956 when he founded Spectrolab, an electrooptical company serving the aerospace industry. His next enterprise, Heliotek (established in 1960 while he was still at Spectrolab), was a semiconductor company that supplied solar cells to power spacecraft and was a vital technology contributor to the then-nascent US space program. Both companies were sold to Textron in 1960, although Mann continued to manage them until 1972. |
|
